2018
DOI: 10.4236/jct.2018.92011
|View full text |Cite
|
Sign up to set email alerts
|

Perioperative Treatment in Gastric Cancer—Developments in Patient Selection

Abstract: Gastric cancer (GC) is a major public health issue. It is considered the 5 th most common cancer diagnosed worldwide and it is one of the main causes of malignant disease-associated morbidity and mortality. The cornerstone of curative treatment is still surgery, and since the rate of relapse is high, a multidisciplinary approach is warranted in most developed countries. And while there have been recent developments in the perioperative scenario namely the FLOT regimen, little has advanced considering patient s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2019
2019

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 13 publications
0
1
0
Order By: Relevance
“…Even though the gastric tumour is classified as Siewert II, it was pondered whether FLOT or CROSS regimens would be the best treatment option. In our institution, Siewert II tumours are usually treated with CROSS regimen and the two drugs of the scheme also are frequently are used in lung cancer, hence it seemed to be the best option [3] [4] [5].…”
Section: Discussionmentioning
confidence: 99%
“…Even though the gastric tumour is classified as Siewert II, it was pondered whether FLOT or CROSS regimens would be the best treatment option. In our institution, Siewert II tumours are usually treated with CROSS regimen and the two drugs of the scheme also are frequently are used in lung cancer, hence it seemed to be the best option [3] [4] [5].…”
Section: Discussionmentioning
confidence: 99%